Melhorn P - Search Results

1

Liver metastases in high-grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in NET G3 versus NEC.

Melhorn P, Raderer M, Mazal P, Berchtold L, Beer L, Kiesewetter B. Melhorn P, et al. J Neuroendocrinol. 2024 Oct 14:e13454. doi: 10.1111/jne.13454. Online ahead of print. J Neuroendocrinol. 2024. PMID: 39402903

2

Thymic malignancies: role of immunotherapy and novel approaches.

Kiesewetter B, Melhorn P, Fuereder T. Kiesewetter B, et al. Among authors: melhorn p. Curr Opin Oncol. 2024 Sep 24. doi: 10.1097/CCO.0000000000001101. Online ahead of print. Curr Opin Oncol. 2024. PMID: 39352276

3

Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.

Kiesewetter B, Pflüger FF, Melhorn P, Mazal P, Raderer M. Kiesewetter B, et al. Among authors: melhorn p. Clin Transl Oncol. 2024 Sep 24. doi: 10.1007/s12094-024-03732-w. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39316250

4

[Current developments in the treatment of neuroendocrine tumors].

Kiesewetter-Wiederkehr B, Melhorn P, Scheuba C, Raderer M. Kiesewetter-Wiederkehr B, et al. Among authors: melhorn p. Radiologie (Heidelb). 2024 Jul;64(7):568-574. doi: 10.1007/s00117-024-01303-2. Epub 2024 Apr 22. Radiologie (Heidelb). 2024. PMID: 38649498 Free PMC article. Review. German.

5

From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.

Melhorn P, Mazal P, Wolff L, Kretschmer-Chott E, Raderer M, Kiesewetter B. Melhorn P, et al. Ther Adv Med Oncol. 2024 Mar 24;16:17588359241240316. doi: 10.1177/17588359241240316. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38529270 Free PMC article. Review.

6

Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms.

Melhorn P, Mazal P, Wolff L, Popov P, Kretschmer-Chott E, Haug A, Mayerhoefer ME, Raderer M, Kiesewetter B. Melhorn P, et al. Endocr Relat Cancer. 2024 Jan 31;31(3):e230151. doi: 10.1530/ERC-23-0151. Print 2024 Mar 1. Endocr Relat Cancer. 2024. PMID: 38214923

7

Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors - Experiences from a tertiary referral center.

Kiesewetter B, Melhorn P, Macheiner S, Wolff L, Kretschmer-Chott E, Haug A, Mazal P, Raderer M. Kiesewetter B, et al. Among authors: melhorn p. J Neuroendocrinol. 2023 Aug;35(8):e13319. doi: 10.1111/jne.13319. Epub 2023 Jul 23. J Neuroendocrinol. 2023. PMID: 37485760

8

Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna.

Melhorn P, Kretschmer-Chott E, Wolff L, Haug A, Mazal P, Raderer M, Kiesewetter B. Melhorn P, et al. Ther Adv Med Oncol. 2022 Nov 19;14:17588359221138389. doi: 10.1177/17588359221138389. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36425874 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters